ClinicalTrials.gov record
Completed Phase 2Phase 3 Interventional Results available

A 6 Week Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD ( Attention Deficit/Hyperactivity )

ClinicalTrials.gov ID: NCT02059642

Public ClinicalTrials.gov record NCT02059642. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 16, 2026, 12:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A 6-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg Compared With Placebo in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)

Study identification

NCT ID
NCT02059642
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2, Phase 3
Lead sponsor
Alcobra Ltd.
Industry
Enrollment
300 participants

Conditions and interventions

Interventions

  • MG01CI (1400 mg) Drug
  • placebo Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 55 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 28, 2014
Primary completion
Aug 31, 2014
Completion
Aug 31, 2014
Last update posted
Mar 27, 2017

2014

United States locations

U.S. sites
18
U.S. states
13
U.S. cities
18
Facility City State ZIP Site status
Sarkis Clinical Trials Gainesville Florida 32607
Miami Research South Miami Florida 33173
Capstone Clinical Research Libertyville Illinois 60048
Psychiatric Associates Overland Park Kansas 66211
University Kentucky Psychiatry Lexington Kentucky 40509
Pediatric Psychopharmacology & Adult ADHD Program, Massachusetts General Hospital Boston Massachusetts 21144
Rochester Center For Behavioral Medicine Rochester Hills Michigan 48307
Behavioral Medicine Center Troy Michigan 48083
St. Charles Psychiatric Associates Saint Charles Missouri 63301
Center for Psychiatry and Behavioral Medicine Las Vegas Nevada 89128
Bioscience Research Mount Kisco New York 10549
Duke University Durham North Carolina 27705
Richard H Weisler, MD, PA Raleigh North Carolina 27609
Sequoia Behavioral Healthcare Media Pennsylvania 19063
FutureResearch Trials Austin Texas 78731
FutureResearch Trials Dallas, LP Dallas Texas 75231
Bayou City Research Houston Texas 77007
NeuroScience, Inc. (NSI) Herndon Virginia 20170

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02059642, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 27, 2017 · Synced May 16, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02059642 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →